AnPac Bio: Surges as co's technology detects pre-cancer diseases in study

Fresh2

14/12/2020 14:41

** U.S.-listed shares of Chinese biotech co  ANPC.O  rise
98% to $8.36 premarket - set for over 8-mth high, if gains hold
    ** ANPC says initial results from follow-up study assessing
over 13,000 individuals with different levels of cancer risk
indicated its screening technology is capable of providing
meaningful information while also picking out pre-cancer
diseases
    ** Co says 20 types of pre-cancer diseases were detected
after initial screening using its Cancer Differentiation
Analysis technology and subsequent confirmation by hospital or
physical testing center health check-ups  urn:newsml:reuters.com:*:nGNXb32Lk7
    ** 92.5% confirmed pre-cancer patients were in medium- to
high-risk cancer groups - Co
    ** Up to Friday's close, stock had fallen 62.5% since its
market debut in January

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))